The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.
endometrial carcinoma
endometrium
immunohistochemistry
no specific molecular profile
oestrogen receptor
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
24
05
2024
received:
05
04
2024
accepted:
25
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
Decreased oestrogen receptor (ER) expression is a marker of poor prognosis in endometrial carcinomas (EC) of no specific molecular profile (NSMP), but the optimal cut-off to separate high-risk 'low ER' versus low-risk 'high ER' expression has not been defined. Here we characterised the distribution of ER staining in a cohort of ECs. Biopsy specimens from 120 cases of NSMP EC were stained for ER and assigned an Allred score. In 66 additional cases ER staining of matched biopsy and hysterectomy were compared. Twelve of 120 tumours had an Allred score of 0-3, including three endometrioid carcinomas (EEA) (one G1, two G3), four clear cell carcinomas (CCC), two mesonephric-like adenocarcinoma (MLA) and one each of: gastric-type adenocarcinoma, carcinosarcoma and endometrial carcinoma NOS. Three had Allred scores of 4-5: two MLA and one high-grade carcinoma with yolk sac differentiation. Five had Allred scores of 6: four EEA (one G1, one G2, two G3) and one mixed clear cell and endometrioid carcinoma. The remaining 100 tumours with Allred scores ≥ 7 were all EEA (66 G1, 28 G2, five G3 and one grade unknown). Comparing the biopsy versus hysterectomy ER staining (n = 66), the results were within a single Allred score point, except two cases with strong diffuse expression in the biopsy (Allred 8) and moderate expression in the hysterectomy (Allred 5). Most NSMP ECs (> 80%) show high ER expression (Allred score ≥ 7). All non-endometrioid carcinomas and a few endometrioid carcinomas had lower ER expression (Allred score ≤ 6) or were completely negative.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Terry Fox Research Institute
Informations de copyright
© 2024 The Author(s). Histopathology published by John Wiley & Sons Ltd.
Références
Felix AS, Stone RA, Chivukula M et al. Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression. Int. J. Cancer 2012; 131; E114–E121.
Kamat AA, Coffey D, Merritt WM et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 2009; 115; 2684–2692.
Jeon YT, Park IA, Kim YB et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 2006; 239; 198–204.
Gehrig PA, Van Le L, Olatidoye B et al. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86; 2083–2089.
Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha‐negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am. J. Obstet. Gynecol. 2008; 199; e1–e7.
Vrede SW, van Weelden WJ, Visser NCM et al. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO‐ESGO‐ESTRO risk classification in endometrial cancer. Gynecol. Oncol. 2021; 161; 787–794.
Jongen V, Briet J, de Jong R et al. Expression of estrogen receptor‐alpha and ‐beta and progesterone receptor‐A and ‐B in a large cohort of patients with endometrioid endometrial cancer. Gynecol. Oncol. 2009; 112; 537–542.
Levine DA. The cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67–73.
Jamieson A, Huvila J, Chiu D et al. Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease‐specific death. Mod. Pathol. 2023; 36; 100085.
Vermij L, Jobsen JJ, Leon‐Castillo A et al. Prognostic refinement of NSMP high‐risk endometrial cancers using oestrogen receptor immunohistochemistry. Br. J. Cancer 2023; 128; 1360–1368.
Crothers BA, Harik LR, Bartley AN et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of gynecologic origin. 2023.
Karnezis AN, Leung S, Magrill J et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J. Pathol. Clin. Res. 2017; 3; 279–293.
Stelloo E, Nout RA, Osse EM et al. Improved risk assessment by integrating molecular and clinicopathological factors in early‐stage endometrial cancer‐combined analysis of the PORTEC cohorts. Clin. Cancer Res. 2016; 22; 4215–4224.
Weinberger V, Bednarikova M, Hausnerova J et al. A novel approach to preoperative risk stratification in endometrial cancer: the added value of immunohistochemical markers. Front. Oncol. 2019; 9; 265.
Cheung CC, D'Arrigo C, Dietel M et al. Evolution of quality assurance for Clinical Immunohistochemistry in the era of precision medicine: part 1: fit‐for‐purpose approach to classification of clinical immunohistochemistry biomarkers. Appl. Immunohistochem. Mol. Morphol. 2017; 25; 4–11.
RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int. J. Gynecol. Cancer 2022; 33; 109–117.
McAlpine JN, Han KCZ, Kinloch M et al. CCTG EN10: a phase II study of tailored adjuvant therapy in POLE‐mutated and p53‐wildtype/NSMP early‐stage endometrial cancer (EC)—RAINBO BLUE and TAPER. J. Clin. Oncol. 2023; 41; TPS5632.
Canadian Cancer Trials Group. Adjuvant therapy in POLE‐mutated and p53‐wildtype/NSMP early stage endometrial cancer RAINBO BLUE & TAPER. Identifier NCT05640999. https://classic.clinicaltrials.gov/ct2/show/NCT05640999.
van Weelden WJ, Reijnen C, Kusters‐Vandevelde HVN et al. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European network for individualized treatment of endometrial cancer collaboration study. Hum. Pathol. 2021; 109; 80–91.
Devereaux KA, Weiel JJ, Pors J et al. Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience. Mod. Pathol. 2022; 35; 688–696.
Allison KH, Hammond MEH, Dowsett M et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J. Clin. Oncol. 2020; 38; 1346–1366.
Fitzgibbons PL, Connolly JL, Committees. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. College of American Pathologists, 2022. https://documents.cap.org/protocols/Breast.Bmk_1.5.0.0.REL_CAPCP.pdf?_gl=1*1f87daq*_ga*MTE4MDI1MzY5My4xNzE4MTIwOTA0*_ga_97ZFJSQQ0X*MTcxODEyMDkwMy4xLjAuMTcxODEyMDkwNC4wLjAuMA
Jerzak KJ, Duska L, MacKay HJ. Endocrine therapy in endometrial cancer: an old dog with new tricks. Gynecol. Oncol. 2019; 153; 175–183.
Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct. Target. Ther. 2020; 5; 137.
Kim HG, Kim H, Yeo MK et al. Mesonephric‐like adenocarcinoma of the uterine corpus: comprehensive analyses of clinicopathological, molecular, and prognostic characteristics with retrospective review of 237 endometrial carcinoma cases. Cancer Genomics Proteomics 2022; 19; 526–539.
McFarland M, Quick CM, McCluggage WG. Hormone receptor‐negative, thyroid transcription factor 1‐positive uterine and ovarian adenocarcinomas: report of a series of mesonephric‐like adenocarcinomas. Histopathology 2016; 68; 1013–1020.
Horn LC, Hohn AK, Krucken I et al. Mesonephric‐like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. J. Cancer Res. Clin. Oncol. 2020; 146; 971–983.
Zhao J, Liu C, Qi JI et al. Mesonephric carcinoma of the uterine corpus: a report of two cases. Oncol. Lett. 2016; 11; 335–339.
Kim SS, Nam JH, Park CH et al. Mesonephric adenocarcinoma of the uterine corpus: a case report and diagnostic pitfall. Int. J. Surg. Pathol. 2016; 24; 153–158.
Wu H, Zhang L, Cao W, Hu Y, Liu Y. Mesonephric adenocarcinoma of the uterine corpus. Int. J. Clin. Exp. Pathol. 2014; 7; 7012–7019.
Ando H, Watanabe Y, Ogawa M et al. Mesonephric adenocarcinoma of the uterine corpus with intracystic growth completely confined to the myometrium: a case report and literature review. Diagn. Pathol. 2017; 12; 1100.
Na K, Kim HS. Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body. Am. J. Surg. Pathol. 2019; 43; 12–25.
Patel V, Kipp B, Schoolmeester JK. Corded and hyalinized mesonephric‐like adenocarcinoma of the uterine corpus: report of a case mimicking endometrioid carcinoma. Hum. Pathol. 2019; 86; 243–248.
Yamamoto S, Sakai Y. Pulmonary metastasis of mesonephric‐like adenocarcinoma arising from the uterine body: a striking mimic of follicular thyroid carcinoma. Histopathology 2019; 74; 651–653.
Kolin DL, Costigan DC, Dong F et al. A combined morphologic and molecular approach to retrospectively identify KRAS‐mutated mesonephric‐like adenocarcinomas of the endometrium. Am. J. Surg. Pathol. 2018; 43; 389–398.
Kenny SL, McBride HA, Jamison J et al. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV‐negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1‐β. Am. J. Surg. Pathol. 2012; 36; 799–807.
Tseng CE, Chen CH, Chen SJ et al. Tumor rupture as an initial manifestation of malignant mesonephric mixed tumor: a case report and review of the literature. Int. J. Clin. Exp. Pathol. 2014; 7; 1212–1217.
Pors J, Cheng A, Leo JM, Kinloch MA, Gilks B, Hoang L. A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric‐like carcinomas of the gynecologic tract. Am. J. Surg. Pathol. 2018; 42; 1596–1606.
Ma T, Chai M, Shou H, Ru G, Zhao M. Mesonephric‐like adenocarcinoma of uterine corpus: a clinicopathological and targeted genomic profiling study in a single institution. Front. Oncol. 2022; 12; 911695.
Euscher ED, Bassett R, Duose DY et al. Mesonephric‐like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior. Am. J. Surg. Pathol. 2020; 44; 429–443.
Hoang LN, McConechy MK, Meng B et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 2015; 66; 664–674.
Ju B, Wang J, Yang B et al. Morphologic and immunohistochemical study of clear cell carcinoma of the uterine endometrium and cervix in comparison to ovarian clear cell carcinoma. Int. J. Gynecol. Pathol. 2018; 37; 388–396.
Ansink AC, Cross PA, Scorer P, de Barros Lopes A, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study. J. Clin. Pathol. 1997; 50; 328–331.
Wong RWC, Ralte A, Grondin K, Talia KL, McCluggage WG. Endometrial gastric (gastrointestinal)‐type mucinous lesions: report of a series illustrating the spectrum of benign and malignant lesions. Am. J. Surg. Pathol. 2020; 44; 406–419.
Wong RWC, Talia KL, McCluggage WG. Endometrial gastric‐type carcinoma: an aggressive and morphologically heterogenous new histotype arising from gastric metaplasia of the endometrium. Am. J. Surg. Pathol. 2020; 44; 1736–1737.
Talhouk A, Hoang LN, McConechy MK et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol. Oncol. 2016; 143; 46–53.